Log in

Galmed Pharmaceuticals News Headlines (NASDAQ:GLMD)

$6.75
+1.05 (+18.42 %)
(As of 12/6/2019 06:17 AM ET)
Today's Range
$5.76
Now: $6.75
$7.38
50-Day Range
$3.67
MA: $4.43
$6.84
52-Week Range
$3.42
Now: $6.75
$9.74
Volume914,231 shs
Average Volume93,876 shs
Market Capitalization$141.87 million
P/E RatioN/A
Dividend YieldN/A
Beta2.9

Headlines

Galmed Pharmaceuticals (NASDAQ GLMD) News Headlines

Source:
DateHeadline
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Given Consensus Rating of "Buy" by AnalystsGalmed Pharmaceuticals Ltd (NASDAQ:GLMD) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - December 5 at 1:54 AM
Canaccord Genuity Initiates Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)Canaccord Genuity Initiates Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)
www.americanbankingnews.com - December 2 at 7:43 AM
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Sees Significant Growth in Short InterestGalmed Pharmaceuticals Ltd (NASDAQ:GLMD) Sees Significant Growth in Short Interest
www.americanbankingnews.com - November 29 at 11:53 AM
Galmed Pharmaceuticals Ltd to Post FY2019 Earnings of ($1.15) Per Share, B. Riley Forecasts (NASDAQ:GLMD)Galmed Pharmaceuticals Ltd to Post FY2019 Earnings of ($1.15) Per Share, B. Riley Forecasts (NASDAQ:GLMD)
www.americanbankingnews.com - November 15 at 11:42 AM
-$0.37 Earnings Per Share Expected for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) This Quarter-$0.37 Earnings Per Share Expected for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) This Quarter
www.americanbankingnews.com - November 13 at 3:39 PM
SunTrust Banks Equities Analysts Boost Earnings Estimates for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)SunTrust Banks Equities Analysts Boost Earnings Estimates for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)
www.americanbankingnews.com - November 11 at 3:37 AM
Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q3 2019 Results - Earnings Call TranscriptGalmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q3 2019 Results - Earnings Call Transcript
seekingalpha.com - November 10 at 1:53 PM
Edited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMTEdited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMT
finance.yahoo.com - November 9 at 1:11 AM
Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial ResultsGalmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
finance.yahoo.com - November 6 at 9:35 AM
Such Is Life: How Galmed Pharmaceuticals (NASDAQ:GLMD) Shareholders Saw Their Shares Drop 60%Such Is Life: How Galmed Pharmaceuticals (NASDAQ:GLMD) Shareholders Saw Their Shares Drop 60%
finance.yahoo.com - November 4 at 2:26 PM
Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019
finance.yahoo.com - October 31 at 9:09 AM
Galmed Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on Wednesday, November 6Galmed Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on Wednesday, November 6
finance.yahoo.com - October 30 at 1:06 PM
GLMD.OQ - Galmed Pharmaceuticals Ltd Profile | ReutersGLMD.OQ - Galmed Pharmaceuticals Ltd Profile | Reuters
www.reuters.com - October 2 at 9:17 PM
Galmed Pharmaceuticals Initiated ARMOR, a Phase 3/4 Registrational Study of Aramchol in Subjects With NASH and FibrosisGalmed Pharmaceuticals Initiated ARMOR, a Phase 3/4 Registrational Study of Aramchol in Subjects With NASH and Fibrosis
finance.yahoo.com - September 26 at 5:27 PM
Should You Buy Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) For This Reason?Should You Buy Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) For This Reason?
finance.yahoo.com - September 19 at 3:38 PM
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2019 Results - Earnings Call TranscriptGalmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - August 5 at 11:40 PM
Edited Transcript of GLMD earnings conference call or presentation 5-Aug-19 12:30pm GMTEdited Transcript of GLMD earnings conference call or presentation 5-Aug-19 12:30pm GMT
finance.yahoo.com - August 5 at 11:40 PM
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial ResultsGalmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results
www.prnewswire.com - August 5 at 7:47 AM
Galmed Pharmaceuticals to Report Second Quarter 2019 Financial Results and Provide Business Update on Monday, August 5Galmed Pharmaceuticals to Report Second Quarter 2019 Financial Results and Provide Business Update on Monday, August 5
finance.yahoo.com - July 29 at 11:21 AM
Could The Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Ownership Structure Tell Us Something Useful?Could The Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Ownership Structure Tell Us Something Useful?
finance.yahoo.com - July 24 at 11:43 PM
Is Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) CEO Being Overpaid?Is Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) CEO Being Overpaid?
finance.yahoo.com - May 23 at 7:25 PM
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2019 Results - Earnings Call TranscriptGalmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 7 at 7:00 PM
Galmed Pharmaceuticals (GLMD) Reports Q1 Loss, Misses Revenue EstimatesGalmed Pharmaceuticals (GLMD) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 7 at 7:00 PM
Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial ResultsGalmed Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 7 at 8:25 AM
Galmed Pharmaceuticals to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 7Galmed Pharmaceuticals to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 7
finance.yahoo.com - April 30 at 6:53 PM
Galmed readies pivotal study of NASH candidate AramcholGalmed readies pivotal study of NASH candidate Aramchol
seekingalpha.com - April 9 at 8:32 AM
Galmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3Galmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3
finance.yahoo.com - April 9 at 8:32 AM
Galmed And Aramchol In NASH, And The Market AssessmentGalmed And Aramchol In NASH, And The Market Assessment
seekingalpha.com - March 28 at 7:26 PM
5 Sizzling Biotech Stocks Under $10 With Gigantic Upside Potential - 24/7 Wall St.5 Sizzling Biotech Stocks Under $10 With Gigantic Upside Potential - 24/7 Wall St.
247wallst.com - March 16 at 8:26 AM
Galmed Pharmaceuticals Ltd.s (GLMD) CEO Allen Baharaff on Q4 2018 Results - Earnings Call TranscriptGalmed Pharmaceuticals Ltd.'s (GLMD) CEO Allen Baharaff on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 14 at 7:20 PM
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2018 Results - Earnings Call TranscriptGalmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 13 at 7:07 PM
Galmed Pharmaceuticals (GLMD) Reports Q4 Loss, Misses Revenue EstimatesGalmed Pharmaceuticals (GLMD) Reports Q4 Loss, Misses Revenue Estimates
finance.yahoo.com - March 13 at 7:07 PM
Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business UpdateGalmed Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
finance.yahoo.com - March 13 at 8:14 AM
Update: Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Gained 95% In The Last Three YearsUpdate: Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Gained 95% In The Last Three Years
finance.yahoo.com - March 12 at 10:49 PM
Galmed Reports Positive Results From Pharmacokinetic Split Dose Study of AramcholGalmed Reports Positive Results From Pharmacokinetic Split Dose Study of Aramchol
finance.yahoo.com - March 12 at 8:31 AM
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2018 Financial Results and Provide Business Update on Wednesday, March 13Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2018 Financial Results and Provide Business Update on Wednesday, March 13
finance.yahoo.com - March 6 at 7:33 PM
Galmed Pharmaceuticals LtdGalmed Pharmaceuticals Ltd
www.bloomberg.com - March 3 at 8:13 AM
Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018
finance.yahoo.com - December 28 at 5:31 PM
What does Galmed Pharmaceuticals Ltd.’s (NASDAQ:GLMD) Balance Sheet Tell Us About Its Future?What does Galmed Pharmaceuticals Ltd.’s (NASDAQ:GLMD) Balance Sheet Tell Us About Its Future?
finance.yahoo.com - December 12 at 4:19 PM
Novan Announces Top-Line Data From Mid-Stage Molluscum Study - NasdaqNovan Announces Top-Line Data From Mid-Stage Molluscum Study - Nasdaq
www.nasdaq.com - December 11 at 5:44 PM
Galmed Pharmaceuticals (GLMD) in Focus: Stock Moves 6.2% HigherGalmed Pharmaceuticals (GLMD) in Focus: Stock Moves 6.2% Higher
finance.yahoo.com - November 20 at 5:20 PM
Galmed: A Deep-Dive Analysis Of The ARREST TrialGalmed: A Deep-Dive Analysis Of The ARREST Trial
seekingalpha.com - November 16 at 5:56 PM
Galmed Pharma (GLMD) Reports Phase 2 Data for Aramchol in Non-Alcoholic SteatohepatitisGalmed Pharma (GLMD) Reports Phase 2 Data for Aramchol in Non-Alcoholic Steatohepatitis
www.streetinsider.com - November 15 at 5:26 PM
Phase 2 Data for Galmed Pharmaceuticals Aramchol™ in Non-Alcoholic Steatohepatitis (NASH) Presented During ...Phase 2 Data for Galmed Pharmaceutical's Aramchol™ in Non-Alcoholic Steatohepatitis (NASH) Presented During ...
www.prnewswire.com - November 15 at 8:20 AM
Phase 2 Data for Galmed Pharmaceuticals Aramchol™ in Non-Alcoholic Steatohepatitis (NASH) Presented During Late-Breaking Abstract Oral Session of The Liver Meeting® 2018Phase 2 Data for Galmed Pharmaceutical's Aramchol™ in Non-Alcoholic Steatohepatitis (NASH) Presented During Late-Breaking Abstract Oral Session of The Liver Meeting® 2018
finance.yahoo.com - November 13 at 5:12 PM
Galmed Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?Galmed Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - November 13 at 8:16 AM
Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q3 2018 Results - Earnings Call TranscriptGalmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 6 at 8:17 AM
Galmed Pharmaceuticals (GLMD) Reports Q3 Loss, Tops Revenue EstimatesGalmed Pharmaceuticals (GLMD) Reports Q3 Loss, Tops Revenue Estimates
www.zacks.com - November 5 at 8:34 AM
Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2018 Financial ResultsGalmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2018 Financial Results
finance.yahoo.com - November 5 at 8:34 AM
Galmed Pharmaceuticals: 3Q Earnings SnapshotGalmed Pharmaceuticals: 3Q Earnings Snapshot
finance.yahoo.com - November 5 at 8:34 AM
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Featured Article: Futures Contract

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel